A recent study detected genes encoding type B botulinum neurotoxin in some type A strains of Clostridium botulinum that exhibit no type B toxin activity. In this study, we investigated the presence, structure, linkage, and organization of genes encoding botulinum neurotoxin (BoNT) and other components of the progenitor complex. Sequence analysis showed that the silent BoNT/B gene is highly related to that from authentic proteolytic type B C. botulinum. However, a stop signal and deletions were found within the sequence. A nontoxin nonhemagglutinin gene ( Clostridium botulinum produces a potent neurotoxin, which causes the severe neuroparalytic illness in humans and animals referred to as botulism. The neurotoxin is serologically differentiated according to its neutralization with type-specific antitoxins into seven types designated by the letters A through G (1). These neurotoxin (BoNT) 1 types are proteins of about 150 kDa, which naturally exist as one of the components of progenitor toxic complexes: as the M complex (about 300 kDa) consisting of BoNT associated with a nontoxic-nonhemagglutinin (NTNH) protein of about 150 kDa, or as the L and LL complexes (about 500 and 900 kDa, respectively) in which the M complex associates with hemagglutinin protein(s) (designated as hemagglutinin 33 (HA-33, about 33 kDa) and hemagglutinin-II (HA-II, about 17 kDa); Refs. 2 and 3). The genes of these components of the toxin complexes are linked in clusters in C. botulinum types A, B, and C (2, 4).
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With the exception of C. botulinum types C and D, strains of C. botulinum usually produce only one neurotoxin type. There are, however, occasional reports of strains that produce two toxin types, of which one is at much higher titer than the other. Examples include types Af, Bf, and Ba (1), where the major toxin type is identified by an uppercase letter and the minor type by a lowercase letter. Franciosa et al. (5) , using polymerase chain reaction (PCR) methodologies, reported the detection of genes encoding type B neurotoxin (BoNT/B) in a large number (43 of 79) of strains of C. botulinum type A, only one of which produced any demonstrable type B toxin. The one producing both toxins would correspond to type Ab according to the above convention. We use the designation A(B) in this article for the strains that produce type A toxin and possess the type B toxin gene, but do not express it. Cordoba et al. (6) recently confirmed the presence of silent or unexpressed BoNT/B genes in some strains of C. botulinum type A using PCR-restriction fragment length polymorphism and probing methodologies.
The surprisingly high frequency of a silent BoNT/B toxin gene in C. botulinum strains producing only type A toxin raises the important question of why the gene is not expressed. Although the silent type B gene was detected by PCR in three of the type A strains (type A(B)) using four different primer pairs or combinations designed for amplification of 5Ј-terminal, central, and 3Ј-terminal regions, as well as nearly the entire gene (5) , sequences within those segments could be altered in major or subtle ways. It is also not known whether genes encoding other components (e.g. NTNH and HA-33) normally associated with BoNT production are present.
This article reports the collaborative work of two laboratories directed toward explaining the silence of the type B gene of C. botulinum A(B) strains. The work at the University of Wisconsin focused on determining the presence, linkage, copy number, and orientation of the genes in the type A and B gene clusters. The Institute of Food Research, Reading Laboratory cloned and sequenced different parts of the A and B gene clusters and analyzed the sequence data. Collectively, the study reveals major alterations in the organization, structure, and expression of the genes encoding proteins of the toxin complexes.
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EXPERIMENTAL PROCEDURES
Cultures and Cultivation-C. botulinum strains were from the culture collection of the Botulism Laboratory of the Centers for Disease Control and Prevention, Atlanta, GA. C. botulinum strain 588 was an Ab strain that produced both A and B toxins, but with B expressed at much lower titers. Strains 519, 593, 667, and 13280 were those identified in the recent study (5) as A(B) strains that produce only A toxin but carry what is considered to be a silent B toxin gene. Strains 62A and 113B were reference strains for the indicated type.
Oligonucleotides-Nonradioactive digoxigenin was used for DNA labeling and detection (the Genius System, Boehringer Mannheim). Oligonucleotides targeting BoNT genes were deliberately designed from nonconserved regions, which were specific for type A or type B toxin genes. Oligonucleotides specific to the HA and NTNH genes were selected from the corresponding published sequences (2-4). The sequences of the oligonucleotides used in this study are shown in Table I .
DNA Preparation and Hybridization-Genomic DNAs were prepared as described previously (8) . The DNA preparations were digested with restriction endonucleases, electrophoresed through agarose gels, blotted onto nylon membranes, and hybridized with specific probes as described previously (8) . PFGE was performed as described previously (8, 9) at 180 V for 18 h, with a ramped pulse time of 0.5-10 s for BamHI, PvuII, and NdeI digests, and at 200 V for 22 h, and a ramped pulse time of 1-40 s for SmaI or XhoI digests.
PCR Amplification and Cloning-PCR at the University of Wisconsin was performed as described previously (8) with slight modifications. Amplification reaction mixtures were first incubated at 93°C for 3 min, followed by 30 cycles with denaturation at 93°C for 1 min, primer annealing at 42°C for 1 min, and primer extension at 72°C for 2 min (10 min for the final cycle). PCR at the Reading Laboratory was performed essentially as described previously (10) except for the following modifications. Denaturation was carried out at 92°C or 94°C for 1 min, annealing at either 39°C or 45°C for 1 min, and extension at 58°C or 72°C for 1.5-5 min (depending on length of fragment) using Ampli-Taq DNA polymerase (Perkin-Elmer). PCR products were cloned from strain C. botulinum 667 A(B) into vector pCR II obtained from Invitrogen (R & D Biosystems, Cowly, United Kingdom), which has overhanging T residues. Ligations were carried out using a ligation kit (Amersham International, Amersham, United Kingdom) according to the manufacturer's instructions. Escherichia coli "One Shot" (Invitrogen) cells were used as the host for transformations.
Sequence Determination-The nucleotide sequences of DNA fragments were based on the sequencing of two or more clones for each fragment derived from separate PCRs. Both strands were sequenced. Analysis of the sequence data was carried out with Wisconsin Molecular Biology software on a VAX computer.
Hemagglutinin Assay-Hemagglutinating activity of all strains of C. botulinum used in this study was assayed by the method of Somers and DasGupta (11), using freshly prepared sheep blood cells.
RESULTS
Confirmation of the Presence of Toxin A and B Genes-PCR
was performed using type A-specific primers (BoNT-832a: BoNT-1789a) and type B-specific primers (BoNT-120b: BoNT1309b) (Table I ) on purified chromosomal DNAs from the four type A(B) strains (519, 593, 667, and 13280), the one type Ab strain (588), and reference strains of type A (62A) and type B (113B) as templates. PCR products of 1.0 kb using type A-specific primer set and 1.1 kb using type B-specific primer set were obtained with templates from the A(B) and Ab strains. Reference strains of type A (62A) and type B (113B) gave products only with the expected primer pairs (data not shown).
For Southern hybridization analyses, chromosomal DNAs were digested with BglII; the fragments were separated by electrophoresis and then hybridized with type A (BoNT-334a) and type B (BoNT-120b) toxin-specific gene probes. Hybridization confirmed the PCR findings with the four type A(B) strains and the Ab strain, giving positive signals with both probes (data not shown).
Presence and Copy Number of Neurotoxin Cluster GenesThe type Ab strain (588) and one type A(B) strain (667) were further analyzed to determine the presence and copy number of BoNT, HA-33, and NTNH genes. Chromosomal DNAs were digested with XbaI, BglII, and HindIII. Southern hybridization was performed using probes BoNT-334a for BoNT/A, BoNT1309b for BoNT/B, NN-180 for NTNH, and Ha-1a for HA-33 genes. The results indicate that both strains 588 and 667 contain one copy of the gene for each neurotoxin (BoNT/A and BoNT/B), two copies of NTNH genes, but only one copy of the HA-33 gene (Fig. 1) . By contrast the reference strains 62A and 113B contain only single copies of the BoNT, NTNH, and HA-33 genes (data not shown).
Linkage and Physical Relationship of BoNT and Other Neurotoxin Cluster Genes-PvuII, BamHI, and NdeI digests of DNAs of 588 and 667 that contained fragments less than 100 kb were separated by PFGE and hybridized with BoNT, BoNT-1a NTNH, and HA gene probes (Fig. 2) . Although digestion profile of 588 was different from that of 667 (data not shown), hybridization patterns with the four gene probes (BoNT-334a, BoNT120b, NN-180, and Ha-1a) were identical. In the PvuII digest, two fragments of 42 and 16 kb hybridized with NN-180 probe (Fig. 2C) . The 42-kb fragment also gave a positive signal with Ha-1a ( Fig. 2D ) and BoNT-120b (Fig. 2B) probes, whereas the 16-kb fragment hybridized with BoNT-334a probe ( Fig. 2A) . In BamHI digests, two fragments (45 and 35 kb) hybridized with NN-180 probe. The 45-kb fragment also hybridized with both Ha-1a and BoNT-120b probes, whereas the smaller fragment produced a positive signal with probe BoNT-334a. Similarly, in NdeI digests, two fragments hybridized with NN-180 probe. One of these also displayed a positive signal with probes Ha-1a and 120b, and the other with probe 334a. These results indicate that single copies of NTNH and HA-33 genes are linked to the BoNT/B gene (designated type B gene cluster). By contrast, the type A gene cluster consists of another copy of NTNH linked to BoNT/A. No HA-33 gene is associated with this latter cluster. In view of the association of HA-33 gene with the silent BoNT/B gene, hemagglutinin activity was assayed (11) . However, no hemagglutinin activity was found in any of the C. botulinum type A(B) or Ab strains examined. To determine the relationship of the type A and B gene clusters, genomic DNAs were digested with rare cut enzymes (SmaI and XhoI), separated by PFGE, and hybridized with BoNT-334a and BoNT-120b probes (Fig. 3) . In SmaI digests, a 106-kb fragment from strain 588 and a 60-kb fragment from strain 667 hybridized with both BoNT-334a and BoNT-120b probes. In XhoI digests, a similar size fragment (80 kb) in strain 588 and 667 was revealed with BoNT-334a and BoNT120b probes. Since type A and B gene clusters themselves constitute a total of approximately 20 kb, these hybridization results suggest the distance between the gene clusters in strains 588 and 667 is less than 60 and 40 kb, respectively.
Characterization and Sequence Analysis of the Type A Gene Cluster-PCR amplification strategies (Fig. 4A) were developed to elucidate the organization of the genes within the type A gene cluster of strain 667 based on universal and specific primers. Two conserved regions within the NTNH gene (corresponding to oligonucleotides NN-20, NN-2100, Table I ) were used as targets for primer design, which, when used in conjunction with oligonucleotides specific for BoNT/A gene, generated fragments covering more than 95% of the NTNH gene. A variety of oligonucleotides targeting HA-33 and HA-II genes were used in combination with NTNH primers but failed to produce amplification products, thereby confirming the absence of hemagglutinin genes within the type A gene cluster (data not shown). Surprisingly, PCR amplification was achieved using NTNH primers in combination with a primer (OR-1) targeting an unidentified open reading frame (ORF) previously reported immediately upstream of the NTNH gene in C. botulinum types E and F (10, 12) . These fragments facilitated the determination of the 5Ј-end of the NTNH gene.
A stretch of approximately 800 bases at the 5Ј-end of the BoNT/A gene was sequenced, which upon computer analysis showed 100% amino acid identity with published BoNT/A (13), thereby confirming its serological assignment. The NTNH gene immediately upstream of BoNT/A gene consisted of an ORF encoding 1162 amino acid residues. Notable was a 33-amino acid deletion (from amino acid 115), which also occurs in the NTNH of non-proteolytic C. botulinum types E and F (14) . The partial sequence of the unidentified ORF linked to NTNH/A gene displayed high homology with the analogous ORF in C. botulinum type E (84.4% amino acid similarity/64.4% identity for a comparison of 82 amino acids) and nonproteolytic type F (96.6% amino acid similarity/89.2% identity).
Characterization and Sequence Analysis of the Type B Gene Cluster-PCR analysis (Fig. 4B) revealed that the arrangement of genes in the type B gene cluster was HA-II, HA-33, P-21, NTNH, and BoNT/B. Because of the considerable size (approximately 10 kb) of the region and number of genes involved, several fragments were generated to be absolutely confident of the linkage and sequences of the various components (Fig. 4B) . Sequence analysis of the HA-33 gene revealed it was of type A, displaying 99.3% amino acid sequence similarity with HA-33 of C. botulinum type A strain NCTC 7272 (Ref. 4 ; Table II ). By contrast, significantly lower amino acid sequence similarities (90.8 -92.8%) were shown with HA-33 of type B C. botulinum. It is worth noting that a major difference between HA-33 genes of strains 667 and NCTC 7272 corresponds to a 4-nucleotide stretch proximal to the 3Ј-end, which in the nucleotide sequence of strain 667 was in fact identical to that reported in nonproteolytic type B C. botulinum (4) . An ORF designated P-21, previously reported in C. botulinum types A and B (4), encoding a protein of 178 amino acids was found linked to the HA-33 gene in the type B gene cluster of strain 667. Pairwise analyses showed the P-21 gene of strain 667 to be more similar to the analogous gene in proteolytic C. botulinum type B than in type A (Table II) . Interestingly, the ShineDalgarno sequence (CCCTCC) of the P-21 gene in strain 667 was also identical to that of proteolytic type B.
The NTNH gene within the type B cluster consisted of an ORF encoding 1198 amino acids. Comparative analysis re- vealed only 92.8% and 88.3% overall amino acid sequence similarity and identity, respectively, with NTNH of proteolytic type B C. botulinum (data not shown). Upon closer inspection, the NTNH gene sequence was found to be unusual; regions of 5Ј-and 3Ј-ends of the gene exhibited high homology (amino acids 1-550, 99.6% and 99.5% sequence similarity and identity; amino acids 1022-1198, 97.7% and 97.2% sequence similarity and identity) with proteolytic type B NTNH, whereas a central stretch of 471 amino acid residues (from amino acids 551 to 1021) displayed much lower relatedness (83.2% and 71.9% sequence similarity and identity). Sequence analysis surprisingly revealed the central moiety of this NTNH to be highly homologous (99.8% and 99.2% amino acids sequence similarity and identity) with the equivalent region of the NTNH gene encoded in the type A cluster. Fig. 5 shows a pairwise comparison of deduced amino acid sequences of NTNH genes within the A and B clusters of the strain 667, and illustrates the "chimeric" nature of the gene in the latter cluster.
The PCR strategy employed (Fig. 4B ) resulted in the determination of 3296 nucleotides of the silent BoNT/B gene, which correspond to the first 3304 nucleotides in the neurotoxin gene sequence from the C. botulinum (proteolytic) strain Danish, published by Whelan et al. (15) . The deviations from the pub- lished nucleotide sequence are listed in Table III . Analysis of the determined sequence revealed a stop codon at amino acid position 128 due to the substitution of a T in place of a G at nucleotide 438. Deletion of nucleotides 1038 -1043 results in amino acid deletions at positions 328 and 329. Interestingly, these amino acid residues are conserved in all published BoNT/A through G neurotoxins (as well as in the tetanus toxin). Two base deletions were also evident in the silent BoNT/B gene at nucleotide position 2389 (T deleted) and 2944 (A deleted). These deletions resulted in multiple stop signals due to two reading frameshifts. Over the course of the 3240 nucleotides corresponding to 3248 nucleotides in the published sequence coding for the amino acids (compensating for the deletions), we found 70 substituted and 8 deleted nucleotides (2.3% deviation). The nucleotide substitutions resulted in the stop codon and 46 amino acid changes, while 23 subsitutions would not have changed the amino acid.
DISCUSSION
The unexpected findings of Franciosa et al. (5) that 42 of 79 strains of Clostridium botulinum type A strains contained a "silent" or unexpressed type B neurotoxin gene raised some interesting questions regarding the origin, structure, and organization of the A and B toxin genes. In the present study, analyses of the genes of the toxin complexes by Southern hybridizations showed that the genome of type A(B) and Ab strains contains one copy of the type A toxin gene, one of the type B toxin gene, two copies of the NTNH gene, and one copy of the HA gene. It was also demonstrated that these genes are distributed into two toxin gene-based clusters, the BoNT/A toxin gene and one of the NTNH genes in one cluster and the remaining genes in a second cluster in the series HA-NTNHBoNT/B toxin gene. Since the alignment of the genes of the second cluster is the same as the analogous genes in C. botulinum type A, B, and E reference strains (6), this does not explain the silence of the type B toxin gene of A(B) strains.
A reasonable explanation for the silence of the type B toxin gene became evident when the nucleotide sequence of the type B toxin gene in strain 667 was determined and compared to that published for a proteolytic C. botulinum type B strain (15) . Although transcription studies are desirable to support the following interpretation, the most striking difference was the finding of a stop codon and two deletions in the gene of the A(B) strain. Although it is not known if the other A(B) strains also possess nucleotide changes that stop expression, this appears to be a likely explanation. The effects of the noted amino acid substitutions and deletions on biological activity if the toxin molecule had been expressed are not known.
The presence on a 60-kb (C. botulinum 667; A(B)) and an 80-kb (C. botulinum 588; Ab) restriction fragment of chromosomal DNAs, which hybridized with the probes for BoNT/A and/B toxin genes, lends the suggestion that less than 40 and 60 kb separate the A and B toxin gene clusters in the genome of those respective strains. However, the observation does not show the orientation of the gene clusters on the chromosome, information that could help in understanding why in strains that produce two toxin types, the toxicity of one of the types is significantly higher than the other. The toxicity ratio of the major to minor toxins is about 10 to 1 in a previously recognized Af strain (16) and about 10,000 to 1 for the Ab strain 588 (5). Such different toxicity levels could result if the molecules are expressed in different quantities, as might occur if the relative positions of the toxin gene clusters affect transcription and/or translation. The gene for the toxin of lower activity may be affected in transcription initiation or termination, or may produce a truncated protein with decreased toxicity. Alternatively, the quantities of toxin molecules synthesized may be similar, but their specific toxicities are different due to changes in protein structure or from postranslational modifications. Transcription and translation experiments would clearly be desirable to investigate the mechanism of low toxin production in the Ab and Af strains.
While the hemagglutinin genes HA-33 and HA-II are present in the type B neurotoxin gene cluster, they do not appear to be expressed, because no hemagglutinin activity was detectable in cultures of strain 667 or in cultures of any of the other four strains possessing both neurotoxin genes. This lack of hemagglutinin expression cannot be dependent on the defective nature of the type B neurotoxin gene, because there was no hemagglutinin expression detected in strain 588, which produces a low level of type B neurotoxin activity. While the HA genes are absent from the type A gene cluster, an unidentified ORF similar to an ORF previously reported only in nonproteolytic type E and F strains was found immediately upstream of the NTNH. Recent observations 2 indicate its occurrence in infant C. botulinum type A strain Kyoto-F.
Although two NTNH genes (one type A and one chimeric) were identified in this study, it is not known if either or both were expressed since there is no known activity or immunologic assay for NTNH. The NTNH gene in the B cluster had a surprising chimeric composition; the nucleotide sequences of the two end regions indicate the gene's type B origin, while the sequence of the central region is more like that of the NTNH gene of a type A organism. The chimeric structure probably arose through recombination events by unknown mechanisms. The chimeric structure of the NTNH also presents an interesting possibility that the expression and structure of this protein may contribute to expression of the neurotoxin gene. Possibly the NTNH gene contains a strong promoter, whose transcription initiates and continues through to the toxin gene. Changes in the structure of this gene could lead to inefficient transcription of the polycistronic RNA encoding the NTNH and toxin proteins.
C. botulinum strains that contain the genes for two toxin types probably arise when a culture producing one toxin type acquires the genes encoding a toxin of a different antigenic type. This transfer possibly involves not only the neurotoxin gene but genes of the entire cluster. The mechanism of transfer is not known but would require a vector capable of transferring large regions of donor DNA. This transfer could occur by bacteriophages or conjugative transposable elements. Our findings confirm the possibility that the botulinal toxin genes are associated with transmissible vectors that can transfer toxicity to normally nontoxigenic clostridia such as Clostridium butyricum and Clostridium baratii, which have been isolated with increasing frequency during the last decade from humans suffering from botulism (1).
